The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First results from the OPTIMA phase III randomized non-inferiority trial of test-directed chemotherapy in patients with high clinical risk ER-positive HER2-negative early breast cancer.
 
Robert Stein
Stock and Other Ownership Interests - GlaxoSmithKline
Research Funding - Veracyte (Inst)
Travel, Accommodations, Expenses - Veracyte
 
Andreas Makris
Honoraria - Lilly; Novartis; Pfizer; Roche
Consulting or Advisory Role - Genzyme; Lilly; Pfizer; Roche
Speakers' Bureau - AstraZeneca; Daiichi-Sankyo; Lilly; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Novartis; Roche
 
Iain Macpherson
Honoraria - Roche
Consulting or Advisory Role - AstraZeneca; BeOne Medicines UK; BeOne Medicines UK; Gilead Sciences; Lilly; Novartis Pharmaceuticals UK Ltd.; Owkin; Pfizer; Roche; Stemline Therapeutics; Veracyte
Speakers' Bureau - Daiichi Sankyo UK Ltd; Menarini; Novartis Pharmaceuticals UK Ltd.
Research Funding - Allarity Therapeutics (Inst); AstraZeneca (Inst); Byondis (Inst); Celldex (Inst); Duality Biologics; Duality Biologics; Jazz Pharmaceuticals; MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi/Aventis (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Novartis Pharmaceuticals UK Ltd.
 
Luke Hughes-Davies
Stock and Other Ownership Interests - Abbvie; Abcam; Alnylam; Amgen; argenx; AstraZeneca; Beam Therapeutics; BeOne Medicines; BioNTech SE; Danaher; Gilead Sciences; GlaxoSmithKline; ImmunityBio; Intellia Therapeutics; intuitive surgical; Johnson & Johnson/Janssen; Lilly; Liquidia Technologies; Medtronic; Merck; Moderna Therapeutics; Novartis; Novo Nordisk; Palantir Technologies; Pfizer; Regeneron; Repare Therapeutics; Roche/Genentech; Sandoz; Syndax; Teva; United Therapeutics; Vertex; Verve Therapeutics; Viking Therapeutics; VIR Biotechnology
 
Andrea Marshall
No Relationships to Disclose
 
Sarah Pinder
Consulting or Advisory Role - Exact Sciences
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Exact Sciences
 
Abeer Shaaban
No Relationships to Disclose
 
Karen Taylor
Research Funding - Veracyte (Inst)
 
Carmel Conefrey
No Relationships to Disclose
 
Mary Falzon
No Relationships to Disclose
 
Bjorn Naume
No Relationships to Disclose
 
Belinda Kiely
Honoraria - AstraZeneca; Eisai; Gilead Sciences; Gilead Sciences; Lilly; MSD Oncology; Novartis
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Novartis; Roche
Travel, Accommodations, Expenses - Lilly; MSD Oncology; Novartis; Novartis; Pfizer; Pfizer
 
David Cameron
Honoraria - AstraZeneca (Inst); Novartis (Inst)
Consulting or Advisory Role - Daiichi Sankyo (Inst); Erytech Pharma (Inst); GRAIL (Inst); Lilly (Inst); Menarini/Stemline Therapeutics (Inst); Novartis (Inst); Nuvectis Pharma (Inst); Pfizer (Inst)
Research Funding - Exact Sciences (Inst); Roche (Inst)
 
Helena Earl
No Relationships to Disclose
 
Daniel Rea
Honoraria - AstraZeneca; Lilly; Novartis; Pfizer; Roche
Speakers' Bureau - AstraZeneca
Research Funding - bioTheranostics (Inst); Celgene (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; eisai; Novartis; Pfizer
 
Peter Hall
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); Lilly (Inst); Novartis (Inst)
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Dxcover (Inst); IQvia (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Okin (Inst); Pfizer (Inst); Roche (Inst); Veracyte (Inst)
 
Adrienne Morgan
No Relationships to Disclose
 
Stuart McIntosh
Honoraria - AstraZeneca (Inst); MSD (Inst); Roche (Inst)
Consulting or Advisory Role - Lilly (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
Speakers' Bureau - AstraZeneca (Inst); Exact Sciences (Inst); MSD (Inst); Roche (Inst); Veracyte (Inst)
Travel, Accommodations, Expenses - Lilly; Novartis; Roche
 
John Bartlett
No Relationships to Disclose
 
Janet Dunn
Research Funding - Veracyte (Inst)